Shanta P. Boddapati, Ph.D. - Publications

Affiliations: 
2011 Chemical Engineering Arizona State University, Tempe, AZ, United States 
Area:
Biomedical Engineering, Molecular Biology, Neuroscience Biology

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Yang G, Velgos SN, Boddapati SP, Sierks MR. Probing antibody-antigen interactions Microbiology Spectrum. 2: 1-13. DOI: 10.1128/microbiolspec. AID-0010-2013  0.534
2013 Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, Sierks MR. Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology Progress. 29: 463-71. PMID 23359572 DOI: 10.1002/Btpr.1698  0.637
2012 Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR. Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. Journal of Alzheimer's Disease : Jad. 28: 961-9. PMID 22156046 DOI: 10.3233/Jad-2011-111196  0.63
2012 Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR. Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of Aging. 33: 1320-8. PMID 21067847 DOI: 10.1016/J.Neurobiolaging.2010.09.020  0.677
2011 Boddapati S, Levites Y, Sierks MR. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. Journal of Molecular Biology. 405: 436-47. PMID 21073877 DOI: 10.1016/J.Jmb.2010.10.054  0.691
2010 Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. Bmc Neuroscience. 11: 57. PMID 20433710 DOI: 10.1186/1471-2202-11-57  0.558
2010 Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry. 49: 4501-8. PMID 20429609 DOI: 10.1021/Bi902030M  0.688
2010 Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnology Progress. 26: 1172-9. PMID 20306540 DOI: 10.1002/Btpr.396  0.687
2009 Wang M, Boddapati S, Sierks M. Response letter to comments on "Cyclodextrins promote protein aggregation posing risks for therapeutic applications". Biochemical and Biophysical Research Communications. 390: 1426-7. PMID 19852940 DOI: 10.1016/J.Bbrc.2009.10.073  0.579
2009 Wang MS, Boddapati S, Sierks MR. Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and Biophysical Research Communications. 386: 526-31. PMID 19540204 DOI: 10.1016/J.Bbrc.2009.06.077  0.684
2008 Boddapati SP, Sierks MR. P2-417: Beta-site specific ScFv's to decrease Abeta generation and toxicity in Alzheimer's disease Alzheimer's & Dementia. 4: T495-T496. DOI: 10.1016/J.Jalz.2008.05.1496  0.63
Show low-probability matches.